Skip to main content
Gufic BioSciences Ltd. logo

Gufic BioSciences Ltd. — Investor Relations & Filings

Ticker · GUFICBIO ISIN · INE742B01025 LEI · 3358003C6YDH6EIDBP63 BSE.NS Manufacturing
Open in API
Filings indexed 1,192 across all filing types
Latest filing 2026-02-13 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS GUFICBIO

About Gufic BioSciences Ltd.

https://gufic.com/

Gufic BioSciences Ltd. focuses on the research, development, and large-scale manufacturing of pharmaceutical formulations and active pharmaceutical ingredients. The organization is distinguished by its specialized expertise in lyophilization technology, operating extensive facilities for the production of freeze-dried injectables. Its product portfolio encompasses a wide range of therapeutic areas, including critical care, infertility, oncology, and gastroenterology. In addition to conventional medicine, the company develops proprietary herbal and ayurvedic formulations through integrated scientific research. Gufic emphasizes advanced drug delivery systems and maintains a significant presence in the production of antibiotics, antifungal agents, and cardiac medications. The company serves a global clientele by providing high-quality generic and specialty healthcare solutions.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from the Board of Directors meeting dated February 13, 2026, which includes approval of unaudited financial results for the quarter and nine months ended December 31, 2025. It contains the unaudited standalone and consolidated financial results with detailed financial data such as revenue, expenses, profit before tax, tax expenses, and net profit. The document also includes limited review reports from the statutory auditors, which are typical for interim or quarterly financial results. The presence of detailed financial statements and auditor review reports for a period shorter than a full fiscal year (quarter and nine months) confirms this is an Interim / Quarterly Report. It is not an announcement of a report publication but the report itself, and it is not a full annual report (10-K). Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2026
2026-02-13 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Gufic Biosciences Limited regarding the approval of unaudited financial results for the quarter and nine months ended December 31, 2025. It includes the unaudited standalone and consolidated financial results along with a limited review report from the statutory auditors. The presence of detailed financial data, including income, expenses, profit before tax, tax expenses, and net profit, indicates this is a comprehensive interim financial report. The document references compliance with Regulation 33 of SEBI Listing Regulations, which pertains to quarterly financial results. The document is about unaudited quarterly and nine months financial results, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but contains substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. 9M 2026
2026-02-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a formal notification from Gufic Biosciences Limited to stock exchanges about an upcoming earnings conference call scheduled for February 16, 2026. It references the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating regulatory compliance. The content is an invitation and details for the earnings call, not the earnings release itself or the transcript. The document length is short (2211 characters), and it serves as an announcement of the event rather than containing financial results or discussion. Therefore, it fits the category of a Call Transcript announcement or invitation, but since it is only the invitation and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event.
2026-02-10 English
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to ....
Regulatory Filings Classification · 95% confidence The document is a notification from Gufic Biosciences Limited to stock exchanges about an upcoming earnings conference call scheduled for February 16, 2026. It references the discussion of business background, prospects, and financial performance, but does not contain any actual financial data or results. The document is short (2211 characters) and serves as an announcement of the call, not the call transcript itself. Therefore, it fits the category of a Call Transcript (CT) only if it contained the full transcript, which it does not. It is not an Earnings Release (ER) because it does not announce financial results, only the call. The best fit is a Regulatory Filing (RNS) as a general announcement under SEBI regulations about the earnings call. Confidence is high due to clear regulatory references and the nature of the document as an announcement.
2026-02-10 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-02-09 English
Board Meeting — Financial Results/Other business matters
Board/Management Information Classification · 95% confidence The document is a notification to stock exchanges about an upcoming Board Meeting scheduled to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements and insider trading regulations. The document does not contain any financial data or results itself, nor does it provide a report. It is an announcement of a board meeting and the expected approval of financial results, not the results or report itself. The document length is short (1802 characters), and it serves as an intimation or notice. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2026-02-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.